Hikma Pharmaceuticals Share Discussion Threads

[joel erickson] 31/5/2019 10:47

Whats happening?

[broadwood] 17/5/2019 07:48

StockMarketWire.com - Hikma Pharmaceuticals said it was on track to meet full-year expectations following a 'good start' to the year, driven by recent product launches and good demand across all three businesses for its products.

Its injectables business was performing well, as strong product demand in the US, more than offsetting increased competition.

In MENA and Europe, Its injectables businesses were on track to deliver 'good growth this year, particularly in our top MENA markets,' the company said.

'We continue to expect global Injectables revenue to be in the range of $850 million to $900 million in 2019,' it added.'We expect core operating margin to be in the range of 35% to 38%.'

In its generics business, the company reiterated its guidance for revenue in the range of $650m to $700m in 2019.

Branded revenue growth, meanwhile, was expected to be in the mid-single digits in constant currency in 2019.

'We have been building on this momentum and 2019 is off to a good start. Across our three businesses, we are driving good demand for our broad product portfolio and recent product launches,' said Siggi Olafsson, Hikma's CEO.

'We continue to strengthen our capabilities, pipeline and business operations, whilst maintaining our focus on cost reduction. I am pleased to reiterate our full year guidance for 2019 and we remain confident in the outlook for the Group and our ability to deliver long-term, sustainable growth.'

[karateboy] 14/3/2019 20:20

Dividend increased by almost 21%. The only reason I see for share price drop is pound strenghing impacting dividend conversion from $ to £. It will recover.

[broadwood] 13/3/2019 14:04

Hikma Pharmaceuticals swung to a profit on Wednesday after it boosted injectables revenue, though it warned of lower sales in its generics business due to price cuts.

For the 12 months to 31 December, the company reported a profit of $408m compared with a loss of $738m a year earlier and revenue increased 8% to $2.07bn.

Its injectables business delivered revenue of $826m a for the year in line with previous guidance for revenues in a range of $825m to $850m.

Going forward, the company expected global Injectables revenue to be in the range of $850m to $900m in 2019, with revenue growth from new product launches and good demand for our in-market portfolio more than offsetting continued price erosion and an easing in demand for products on shortage.

Core operating margin for injectables was expected in the range of 35% to 38% in 2019.

Full-year generics revenue rose 13% to $692m, in with expectations for revenues between $675m and $700m.

Generics were expected to generate revenue between $650m to $700m in 2019.

'We expect Branded revenue to grow in the mid-single digits in constant currency in 2019 Looking beyond 2019, we expect to benefit from our continued investment in R&D across our businesses and we will look to fill pipeline gaps through business development,' the company said.

[rafieh] 13/3/2019 12:27

Well, not sure. I think the buyers would want the valuation to come down first before they seriously consider this.

[bantam175] 13/3/2019 10:13

Raf get back in quick if I was you. Bounce coming.

[bantam175] 13/3/2019 09:31

Not unexpected. Should be fine long term.

My portfolio now 90% companies that operate outside the UK. Only registered on the ftse.

[rafieh] 13/3/2019 09:27

Same here. Got stopped out at 1618

[samenic] 13/3/2019 09:08

Read thru results can't really understand the reaction

[bantam175] 13/3/2019 08:20

Don't count on it. But I hope you're right.

The old adage buy on rumour sell on news still applies for many.

Still, fine results and once all is sorted they should rise.


imo dyor etc etc.

[rafieh] 13/3/2019 08:12

Still the share price will be up today.

[bantam175] 13/3/2019 07:59

Shame it's come at the same time as this Brexit mess. :-(

[rafieh] 13/3/2019 07:25

Results look solid. share price should move to 20 pounds mark and beyond.

[robertball] 19/12/2018 08:40

Sector activity

[bantam175] 12/11/2018 08:13

Below where we were before the announcement now .. Nuts.

IMHO it's only a matter of time before a return to the 100 and a rerating to around £24 ps.

Hopefully followed by a making up with the FDA then who knows?

Odd there always seems to be a big drop before a big surge.

Downgrade from Peel Hunt this morning from add to hold, although they have actually raised their target price?

[joshuam] 10/11/2018 13:04

That was a kick

[robertball] 09/11/2018 19:38

I suppose. I reckon half of any gain is given up. So long as trend is intact

[mayers] 09/11/2018 17:22

Profit taking on announcement and at an apparent resistance level I imagine, Robertball.